Vol 7, Supplement 1 (February 2018): Translational Cancer Research


HSP90 inhibitors for high-grade glioma treatment
George A. Alexiou, Athanasios P. Kyritsis
Editorial on MSKCC prospective validation study of ACOSOG Z0011 Trial—what have we learned?
Emanuela Esposito
Does ipilimumab show an increased clinical benefit when combined in sequence with chemotherapy?
Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura
Novel mechanisms of chemoresistance by Fusobacterium nucleatum involve not so novel pathways of microRNAs and autophagy
Mandip KC, Clifford J. Steer
Smooth sailing for immunotherapy for unresectable stage III nonsmall cell lung cancer: the PACIFIC study
Melin J. Khandekar, Rakesh Jain
Intratumoral bacteria as potential contributor of gemcitabine resistance
Melanie S. Patzak, Volker Ellenrieder, Albrecht Neesse
Prostate-specific membrane antigen and renal cell carcinoma: a new diagnostic and therapeutic target?
Federica Matteucci, Giovanni Paganelli
Icotinib improves progression free survival in epidermal growth factor receptor positive non-small cell lung cancer patients
Pranav Gupta, Anna Maria Barbuti, De-Shen Wang, Qingbin Cui, Zhe-Sheng Chen
Oncogenic insult to the brain: sox proteins rise to the occasion
Hannah M. Wüst, Michael Wegner
Oxygen starvation during T cell priming boosts cancer-killing potential
Špela Konjar, Birte Blankenhaus, Marc Veldhoen
A circRNA/miR axis contributes to hypoxia-induced cardiomyocyte death
Paola Costelli
Checkpoint inhibitors after chemoradiation: is it ready for prime time?
Carlos Rojas, Vamsidhar Velcheti
CircMTO1: a novel regulator of hepatocellular carcinoma progression
Xuechao Wan, Yao Li
Genomic scores are independent of disease volume in men with favorable risk prostate cancer—implications for choosing men for active surveillance
Guillaume Ploussard, Ambroise Salin, Igor Latorzeff
Circular RNA: non-coding RNA with emerging roles in stem cell differentiation
Anuradha Moirangthem, Tushar Patel
New hope for advanced nasopharyngeal cancer—an Epstein-Barr virus-driven endemic malignancy?
Victor Ho Fun Lee, Sum-Yin Chan, Chi-Chung Tong, Ka-On Lam, Dora Lai-Wan Kwong, To- Wai Leung, Anne Wing-Mui Lee
Editorial on “PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
David Escors, Grazyna Kochan
CRISPR-based genetic interaction maps inform therapeutic strategies in cancer
Poornima Ramkumar, Martin Kampmann
A novel window opened: EBV-driven enhancer-promoter loops in lymphocytic immortalization
Shen Li, Jianhong Lu
S100A4, a key factor in glioblastoma biology
Christine Decaestecker, Sarah De Clercq, Isabelle Salmon
Editorial on “Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial”
Matteo Santoni, Alessandro Conti, Rodolfo Montironi, Nicola Battelli
Circular RNA shifts the miRNA binding panel and takes a role in hepatocellular carcinoma progression
Jinglei Liu, Nu Zhang
Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents
Sri Harsha Tella, Anuhya Kommalapati, Ryan K. Singhi
The importance of galectin-3 as a novel target for lung cancer patients harboring KRAS mutation
Kang-Seo Park, Dae Ho Lee
Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
Narjust Duma, Aaron S. Mansfield
Lymph node positive prostate cancer: the evolving role of adjuvant therapy
Juan J. Chipollini, Julio M. Pow-Sang

Letter to the Editors

Multiscale modeling of glioblastoma
Huaming Yan, Mónica Romero-López, Lesly I. Benitez, Kaijun Di, Hermann B. Frieboes, Christopher C. W. Hughes, Daniela A. Bota, John S. Lowengrub